TVGN — Tevogen Bio Holdings Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1860871 ·
Last close
$8.60
Market Cap
$36.01M
52W High
$14.15
52W Low
$4.14
ADV30
26,171
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,400,920 | -5,446,255 | 4,921,005 | 692,305 | 14,763,163 |
| Dec 2025 | 0 | — | -4,610,201 | -4,677,580 | 4,382,994 | 552,372 | 12,617,720 |
| Sep 2025 | 0 | — | -5,729,431 | -5,726,812 | 4,493,669 | 1,037,094 | 12,317,565 |
| Jun 2025 | 0 | — | -5,444,536 | -5,503,979 | 4,269,136 | 685,229 | 13,753,878 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,328,577
Investing CF
$0
Financing CF
$11,662,393
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.00
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-139,660,549
Inventory
—
Receivables
$158,819
ST Investments
—
EBIT TTM
$-26,058,404
Pretax Income TTM
$-26,275,432
Interest Exp TTM
$173,383
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -26,140,515 | -26,275,432 | 4,382,994 | 12,617,720 | — | -12,328,577 |
| Dec 2024 | 0 | -53,564,488 | -13,727,380 | 3,461,675 | 10,135,680 | — | -11,998,730 |
| Dec 2023 | 0 | -8,843,025 | -60,477,680 | 5,505,503 | 99,934,400 | — | -8,171,118 |
| Dec 2022 | 0 | -953,083 | 4,408,361 | 357,138,356 | 15,057,704 | — | -215,395 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EVAX | Evaxion A/S | $34.28M | $4.11 | — |
| INMB | Inmune Bio, Inc. | $38.02M | $1.43 | — |
| ENZN | Viskase Holdings, Inc. | $38.02M | $5.75 | — |
| ALGS | Aligos Therapeutics, Inc. | $30.93M | $5.74 | — |
| SNTI | Senti Biosciences, Inc. | $30.90M | $0.99 | — |
News headlines (Yahoo Finance, 1h cache)
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
2026-05-21 16:15 · Yahoo
Letter to Shareholders from CEO Dr. Ryan Saadi
2026-05-18 16:15 · Yahoo
Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
2026-05-12 15:45 · Yahoo
Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization
2026-05-05 01:24 · Yahoo
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
2026-04-27 15:50 · Yahoo
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
2026-03-26 16:45 · Yahoo
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-03-25 18:20 · Yahoo
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
2026-03-18 16:22 · Yahoo
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
2026-03-13 18:45 · Yahoo
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
2026-03-13 16:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.